A new TAG-72 cancer marker peptide identified by phage display

Cancer Letters

Volumn 272, Issue 1, 2008, Pages 122-132

  Chen, Ling ^a   Wang, Yi ^a   Liu, Xinrong ^a   Dou, Shuping ^a   Liu, Guozheng ^a   Hnatowich, Donald J ^a   Rusckowski, Mary ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Peptide biomarker; Phage display; TAG 72; Tumor imaging

Indexed keywords

GLYCYLGLYCYLVALYLSERYLCYSTEINYLMETHIONYLGLUTAMINYLTHREONYLSERYLPROLYLVALYLCYSTEI NYLGLUTAMYLASPARAGINYLASPARAGINYLLEUCINE; TAG 72 ANTIGEN; THREONYLLYSYLARGINYLASPARTYLCYSTEINYLSERYLALANYLGLUTAMINYLASPARAGINYLTYROSYLGLYC YLCYSTEINYLGLUTAMINYLLYSYLALANYLISOLEUCINE; TUMOR MARKER; UNCLASSIFIED DRUG; VALYLHISTIDYLHISTIDYLSERYLCYSTEINYLTHREONYLLYSYLLEUCYLTHREONYLHISTIDYLCYSTEINYLC YSTEINYLGLUTAMINYLASPARAGINYLTRYPTOPHYLHISTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BACTERIOPHAGES; BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; CONSENSUS SEQUENCE; DNA PRIMERS; FLOW CYTOMETRY; GLYCOPROTEINS; HT29 CELLS; HUMANS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; TUMOR MARKERS, BIOLOGICAL;

EID: 53949085983     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.009     Document Type: Article

References (25)

1. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24 (2003) 389-427
2. Krenning E.P., Bakker W.H., Breeman W.A., Koper J.W., Kooij P.P., Ausema L., Lameris J.S., Reubi J.C., and Lamberts S.W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1 (1989) 242-244
3. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., and Maecke H.R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417-418
4. Kwekkeboom D.J., Bakker W.H., Kam B.L., Teunissen J.J., Kooij P.P., de Herder W.W., Feelders R.A., van Eijck C.H., de Jong M., Srinivasan A., Erion J.L., and Krenning E.P. Treatment of patients with gastro-enteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 417-422
5. Lantry L.E., Cappelletti E., Maddalena1 M.E., Fox J.S., Feng W., Chen J., Thomas R., Eaton S.M., Bogdan N.J., Arunachalam T., Reubi J.C., Raju N., Metcalfe E.C., Lattuada L., Linder K.E., Swenson R.E., Tweedle M.F., and Nunn A.D. Nunn1, 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J. Nucl. Med. 47 (2006) 1144-1152
6. Markwalder R., and Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59 (1999) 1152-1159
7. Van de Wiele C., Dumont F., Vanden Broecke R., Oosterlinck W., Cocquyt V., Serreyn R., Peers S., Thornback J., Slegers G., and Dierckx R.A. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med. 27 (2000) 1694-1699
8. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 1378-1382
9. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., and Maecke H.R. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor expressing tumors. Cancer Res. 64 (2004) 6707-6715
10. Nock B.A., Nikolopoulou A., Galanis A., Cordopatis P., Waser B., Reubi J.C., and Maina T. Potent bombesin-like peptides for GRPreceptor targeting of tumors with 99mTc: a preclinical study. J. Med. Chem. 48 (2005) 100-110
11. Pasqualini R., and Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 380 (1996) 364-366
12. Askoxylakis V., Mier W., Zitzmann S., Ehemann V., Zhang J., Krämer S., Beck C., Schwab M., Eisenhut M., and Haberkorn U. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. J. Nucl. Med. 47 (2006) 981-988
13. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
14. Thor A., Ohuchi N., Szpak C.A., Johnston W.W., and Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46 (1986) 3118-3124
15. Stramignoni D., Bowen R., Atkinson B.F., and Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int. J. Cancer 31 (1982) 543-552
16. Nuti M., Teramoto Y.A., Mariani-Costantini R., Hand P.H., Colcher D., and Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer 29 (1982) 539-545
17. Milenic D.E., Roselli M., Brechbiel M.W., Pippin C.G., McMurray T.J., Carrasquillo J.A., Colcher D., Lambrecht R., Gansow O.A., and Schlom J. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. Eur. J. Nucl. Med. 25 (1998) 471-480
18. Colcher D., Hand P., Nuti M., and Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Nat. Acad. Sci. USA 78 (1981) 3199-3203
19. Rusckowski M., Gupta S., Liu G., Dou S., and Hnatowich D.J. Evidence of specificity of radiolabeled phage display peptides for the TAG-72 antigen. Cancer Biother. Radiopharm. 22 (2007) 564-572
20. Bonnycastle L.L.C., Menendez A., and Scott J.K. General phage methods page. In: Barbas III C.F., Burton D.R., Scott J.K., and Silverman G.J. (Eds). Phage Display: A Laboratory Manual (2001), Cold Spring Harbor Laboratory Press, New York 15.1-15.30
21. 99mTc using an NHS-MAG3 bifunctional chelator. J. Nucl. Med. 39 (1998) 56-64
22. 99mTc-labeled bacteriophage as a potential infection-specific imaging agent. J. Nucl. Med. 45 (2004) 1201-1208
23. Hand H.P., Colcher D., Salomon D., Ridge J., Noguchi P., and Schlom J. Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res. 45 (1985) 833-840
24. Gui J., Moyana T., Malcolm B., and Xiang J. Identification of a decapeptide with the binding reactivity for tumor-associated TAG72 antigen from a phage displayed library. Proteins 24 (1996) 352-358
25. Gui J., Moyana T., and Xiang J. Selection of a peptide with affinity for the tumor-associated TAG72 antigen from a phage-displayed library. Biochem. Biophys. Res. Commun. 218 (1996) 414-419